Drug intelligence / Profile preview

BL-3000

Development stage: Phase 3
Lead developer: Biolab Farmacêutica
Modality: Small Molecules
Administration: Oral

Overview

**BL-3000** is an oral investigational fixed-dose capsule developed by **Biolab** for the treatment of telogen effluvium in women. It was evaluated in the randomized, double-dummy, placebo-controlled Phase III trial NCT04880889, which compared once-daily BL-3000 for 180 days with Pantogar. Secondary clinical-trial registry data identify the active ingredients as pantothenic acid and thiamine, although the primary ClinicalTrials.gov record does not provide a composition or molecular mechanism for BL-3000.

Beyond the preview

Go deeper on BL-3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-3000.

Explore the full profile